1 active not recruiting, 1 terminated, 1 unknown. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Terminated 1, Unknown 1 |
Follow Mamta Parikh: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma Pembrolizumab, Selinexor - Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Terminated | Mamta Parikh | 4 | 2021-04-08 | 2026-01-29 |
| Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Enzalutamide, Indomethacin - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 1 / Phase 2 | Unknown | Mamta Parikh | 38 | 2017-01-17 | 2023-11-29 |
| Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Abiraterone Acetate, Niclosamide, Prednisone - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Active not recruiting | Mamta Parikh | 37 | 2016-10-01 | 2024-12-18 |
Prostatic Neoplasms (2) · Carcinoma, Transitional Cell (1)
Abiraterone Acetate (1) · Indomethacin (1) · Niclosamide (1) · Prednisone (1) · deltacortene (1) · enzalutamide (1) · pembrolizumab (1) · selinexor (1)
United States (3)
Chong-Xian Pan (1)
P30CA093373 (3)